Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in France / NCT03595787
Active, not recruiting Not applicable

COaching and Prehabilitation: Faisability Study in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome

NCT03595787 · tracked via the Priya Life Science France tracker
Sponsor
Institut Paoli-Calmettes
Phase
Not applicable
Started
2022-04-04
Last updated
2024-12-18

Condition(s) studied

Acute Myeloid LeukemiaMyelodysplastic Syndromes

Investigational drug(s) / intervention(s)

Coaching and Habilitation

Coaching and Habilitation: nutritional support, adapted physical activity and coaching

Study summary

This faisability study aims to evaluate the adhesion of the patient to a multidisciplinary program (adapted physical activity, coaching and nutrition)

Eligibility

Sex
ALL
Min age
18 Years
Max age
70 Years
Healthy volunteers
No
Inclusion Criteria: * Diagnosis of acute myeloid leukemia or high-risk myelodysplastic syndrome * Age between 18 and 70 years * Eligible for an intensive chemotherapy * Eligible for allograft * Able to answer a questionnaire Exclusion Criteria: * Diagnosis of acute promyelocytic Leukemia * Palliative treatment * Contraindication to moderate physical activity * Performans status 4, unless it is related to the disease * Patient who does not understand French * Patient unable to use a smartphone * Patient deprived of liberty or placed under the authority of a tutor, * Patient considered socially or psychologically unable to comply with the treatment and the required medical follow-up.

Primary outcome measure(s)

  • feasibility to the adapted multidisciplinary program — 6 months
    proportion of patients who will complete more than 50% of the APA/coaching sessions prescribed

Trial sites (1)

FacilityCityRegionStatus
Institut Paoli Calmettes Marseille France

More Institut Paoli-Calmettes trials in France

Institut Paoli Calmettes Chronic Lymphatic Leukemia Database Recruiting
Efficacy of First-Line Gemcitabine Chemotherapy in GemCore+ Metastatic Pancreatic Adenocarcinoma Patients Recruiting
Feasibility Study of a Sports-Inspired Onco-Coaching Progranm for Young Adults i Cancer Remission Recruiting
Genetic Predisposition to Breast and Ovarian Cancer: Prospective Study of BRCAx Gene Mutation Recruiting
Immunological Follow-up After Allogeneic Hematopoietic Stem Cell Transplantation Active, not recruiting

Other trials for the same condition

Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors Recruiting
Registry of Myelodysplastic Syndromes and Therapy-related Acute Myeloid Leukemia Recruiting
Study of the Relationship Between the Pharmacokinetics (PK) and Pharmacodynamics of Venetoclax in Patients With Acute Myeloblastic Leukemia Recruiting
Biocollection in MyeloDysplastic Syndrome (P-MDS) Recruiting
A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML) Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT03595787 on ClinicalTrials.gov ↗ ← All trials in France